Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 324 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemoglobin Clear all
Completed Phase 2 Interventional Results available

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

NCT03264989
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 12, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
vadadustat, epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Bakersfield, California • Elk Grove, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Not applicable Interventional

Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus

NCT00985361
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Vitamin D3 2000 international units daily, Vitamin C 500mg daily
Dietary Supplement
Lead sponsor
ProMedica Health System
Other
Eligibility
21 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Sylvania, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Sep 12, 2026, 3:59 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT00387972
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
denagliptin (GW823093)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
57
States / cities
Tallassee, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Phase 1 Interventional

Self Monitoring of Blood Glucose With Finger Tip vs. Alternate Site Sampling: Effect on Long Term Glycemic Control

NCT00207207
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alternate site blood glucose testing
Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 12, 2026, 3:59 AM EDT
Terminated Phase 1 Interventional

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

NCT07431398
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Pociredir
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Riverdale, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 12, 2026, 3:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

NCT05828108
View directory record Official record
Conditions
Steroid-refractory Diamond-Blackfan Anemia (DBA)
Interventions
Bitopertin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.

NCT05145439
View directory record Official record
Conditions
Diabetic Foot Ulcer, Peripheral Arterial Disease, Wound; Foot
Interventions
VibratoSleeve Therapeutic Ultrasound Device
Device
Lead sponsor
Vibrato Medical, Inc.
Industry
Eligibility
22 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 12, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)

NCT02640573
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

NCT01398943
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tetrahydrobiopterin (BH4), Antioxidant Cocktail
Drug · Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

NCT01736683
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Sotatercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
13
States / cities
Denver, Colorado • Tampa, Florida • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes

NCT01142297
View directory record Official record
Conditions
Partially Edentulous Mandible, Type 2 Diabetes
Interventions
dental implant and modified dental implant
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 12, 2026, 3:59 AM EDT
Withdrawn Not applicable Interventional

Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes

NCT02400450
View directory record Official record
Conditions
Pre-Diabetes
Interventions
Functional Ingredient Group, Control Ingredient Group
Dietary Supplement
Lead sponsor
University of Manitoba
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 12, 2026, 3:59 AM EDT
Terminated Phase 3 Interventional Results available

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

NCT00294723
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, glimepiride, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
102
States / cities
Concord, California • Escondido, California • Fullerton, California + 83 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 12, 2026, 3:59 AM EDT
Not listed Phase 3 Interventional

Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)

NCT04239391
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Loma Linda, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Phase 3 Interventional

Premature Infants in Need of Transfusion (PINT)

NCT00182390
View directory record Official record
Conditions
Anemia of Prematurity
Interventions
Red blood cell transfusion
Procedure
Lead sponsor
McMaster University
Other
Eligibility
Up to 48 Hours
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Albany, New York • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 12, 2026, 3:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Sampling for Research Related to Sickle Cell Disease

NCT00542230
View directory record Official record
Conditions
Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

NCT02225132
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
15 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 12, 2026, 3:59 AM EDT
Withdrawn Phase 4 Interventional

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

NCT00657514
View directory record Official record
Conditions
Peripheral Arterial Disease, Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Colorado Prevention Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease - Pilot Intervention Study

NCT00850018
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Monthly blood transfusion regimen, Usual care
Procedure · Behavioral
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
21 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
14
States / cities
Oakland, California • Washington D.C., District of Columbia • Hollywood, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

New Ways to Help Patients Improve Their Diabetes Control

NCT01143870
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
"Diabetes Report Card"
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 12, 2026, 3:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 12, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strategies to Reduce Iron Deficiency

NCT02245321
View directory record Official record
Conditions
Iron Deficiency
Interventions
Ferrous gluconate- 19 mg, Ferrous gluconate- 38 mg, Letter Group- Information Provided, Letter - No Information Provided, Placebo
Dietary Supplement · Other
Lead sponsor
Westat
Other
Eligibility
18 Years to 100 Years
Enrollment
702 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
4
States / cities
Farmington, Connecticut • Rockville, Maryland • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 12, 2026, 3:59 AM EDT